J I Silverberg1,2, D Lei2, M Yousaf2, S R Janmohamed2, P P Vakharia3, R Chopra4, R Chavda5, S Gabriel5, K R Patel6, V Singam7, R Kantor4, D Y Hsu2. 1. Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 2. Department of Dermatology, Universitair Ziekenhuis Brussel (UZB), Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, Jette, 1090, Belgium. 3. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. State University of New York Downstate Medical Center, Brooklyn, NY, USA. 5. Galderma SA, Rx Strategy & Innovation Group, La Tour-de-Peliz, Switzerland. 6. Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 7. Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA.
Abstract
BACKGROUND: Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs is not well established across all severities of atopic dermatitis (AD). OBJECTIVES: To determine the MIC of percentage and absolute improvement of EASI and SCORAD scores in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 826). An anchor-based approach was used to determine thresholds for the percentage and absolute MICs of EASI, SCORAD and objective SCORAD (O-SCORAD) at follow-up from baseline. RESULTS: One-grade improvements of Physician's Global Assessment (PGA) and validated Investigator Global Assessment scale for AD (vIGA-AD) were associated with 50%, 35% and 35% decreases of EASI, SCORAD and O-SCORAD, respectively. The thresholds for percentage MIC of EASI (Kruskal-Wallis test, P = 0·61), SCORAD (P = 0·07) and O-SCORAD (P = 0·09) were similar across baseline AD severities. One-grade improvements of PGA and vIGA-AD were associated with 14·0- and 14·9-point decreases of EASI, 19·9- and 14·9-point decreases of SCORAD, and 15·5- and 17·4-point decreases of O-SCORAD. The thresholds for the absolute MIC of EASI (P < 0·001), SCORAD (P < 0·001) and O-SCORAD (P < 0·001) significantly differed by baseline AD severity. Percentage and absolute MICs for EASI and SCORAD were associated with improvements of AD symptoms and quality of life. CONCLUSIONS: EASI 50, SCORAD 35 and O-SCORAD 35 were meaningful percentage MICs regardless of baseline AD severity. The absolute MICs for EASI, SCORAD and O-SCORAD varied by baseline AD severity.
BACKGROUND: Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs is not well established across all severities of atopic dermatitis (AD). OBJECTIVES: To determine the MIC of percentage and absolute improvement of EASI and SCORAD scores in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 826). An anchor-based approach was used to determine thresholds for the percentage and absolute MICs of EASI, SCORAD and objective SCORAD (O-SCORAD) at follow-up from baseline. RESULTS: One-grade improvements of Physician's Global Assessment (PGA) and validated Investigator Global Assessment scale for AD (vIGA-AD) were associated with 50%, 35% and 35% decreases of EASI, SCORAD and O-SCORAD, respectively. The thresholds for percentage MIC of EASI (Kruskal-Wallis test, P = 0·61), SCORAD (P = 0·07) and O-SCORAD (P = 0·09) were similar across baseline AD severities. One-grade improvements of PGA and vIGA-AD were associated with 14·0- and 14·9-point decreases of EASI, 19·9- and 14·9-point decreases of SCORAD, and 15·5- and 17·4-point decreases of O-SCORAD. The thresholds for the absolute MIC of EASI (P < 0·001), SCORAD (P < 0·001) and O-SCORAD (P < 0·001) significantly differed by baseline AD severity. Percentage and absolute MICs for EASI and SCORAD were associated with improvements of AD symptoms and quality of life. CONCLUSIONS: EASI 50, SCORAD 35 and O-SCORAD 35 were meaningful percentage MICs regardless of baseline AD severity. The absolute MICs for EASI, SCORAD and O-SCORAD varied by baseline AD severity.
Authors: Rishi Chopra; Paras P Vakharia; Ryan Sacotte; Neha Patel; Supriya Immaneni; Takeshia White; Robert Kantor; Derek Y Hsu; Jonathan I Silverberg Journal: J Allergy Clin Immunol Date: 2017-06-15 Impact factor: 10.793
Authors: L A A Gerbens; C A C Prinsen; J R Chalmers; A M Drucker; L B von Kobyletzki; J Limpens; H Nankervis; Å Svensson; C B Terwee; J Zhang; C J Apfelbacher; P I Spuls Journal: Allergy Date: 2016-07-13 Impact factor: 13.146
Authors: Mary K Hill; Azin Kheirandish Pishkenari; Taylor L Braunberger; April W Armstrong; Cory A Dunnick Journal: J Am Acad Dermatol Date: 2016-09-08 Impact factor: 11.527
Authors: Zelma C Chiesa Fuxench; Julie K Block; Mark Boguniewicz; John Boyle; Luz Fonacier; Joel M Gelfand; Mitchell H Grayson; David J Margolis; Lynda Mitchell; Jonathan I Silverberg; Lawrence Schwartz; Eric L Simpson; Peck Y Ong Journal: J Invest Dermatol Date: 2018-10-30 Impact factor: 8.551
Authors: Jonathan I Silverberg; Eric L Simpson; Mark Boguniewicz; Marjolein S De Bruin-Weller; Peter Foley; Yoko Kataoka; Gaëlle Bégo-Le-Bagousse; Zhen Chen; Brad Shumel; Jingdong Chao; Ana B Rossi Journal: Acta Derm Venereol Date: 2021-11-10 Impact factor: 3.875
Authors: Jon M Hanifin; Wenelia Baghoomian; Erin Grinich; Yael A Leshem; Michael Jacobson; Eric Lawrence Simpson Journal: Dermatitis Date: 2022 May-Jun 01 Impact factor: 4.867
Authors: Lawrence F Eichenfield; April Armstrong; Emma Guttman-Yassky; Peter A Lio; Chi-Chang Chen; Dionne M Hines; Catherine B McGuiness; Sohini Ganguli; Dimittri Delevry; Debra Sierka; Usha G Mallya Journal: Dermatol Ther (Heidelb) Date: 2022-05-11
Authors: Jonathan I Silverberg; David N Adam; Matthew Zirwas; Sunil Kalia; Jan Gutermuth; Andreas Pinter; Andrew E Pink; Andrea Chiricozzi; Sebastien Barbarot; Thomas Mark; Ann-Marie Tindberg; Stephan Weidinger Journal: Am J Clin Dermatol Date: 2022-07-20 Impact factor: 6.233
Authors: Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg Journal: J Invest Dermatol Date: 2021-08-02 Impact factor: 8.551